Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nadunolimab + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Cantargia
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Nadunolimab + pembrolizumab is a combination therapy consisting of nadunolimab, an IL1RAP (IL-1 receptor accessory protein)-targeting antibody that blocks IL-1α/IL-1β signaling and has enhanced antibody-dependent cellular cytotoxicity, and pembrolizumab (Keytruda), an established PD-1 checkpoint inhibitor. This combination is being investigated for patients with solid tumors who have progressed on previous checkpoint inhibitor treatment, suggesting acquired checkpoint inhibitor resistance.
- Brand names
- Keytruda
- Other names
- CAN04 plus pembrolizumabCAN-04 plus pembrolizumabCAN 04 plus pembrolizumabnadunolimab plus pembrolizumab
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on nadunolimab + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nadunolimab + pembrolizumab.